The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately to severely active ulcerative colitis. This marks a significant milestone as SKYRIZI becomes the first IL-23 specific inhibitor approved for this condition, in addition to its approval for moderate to […]
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic move in the biopharmaceutical sector focused on the development of novel treatments for autoimmune diseases. The definitive agreement outlines AbbVie’s acquisition of Landos, a clinical-stage biopharmaceutical company renowned for its innovative approach to creating oral therapeutics for […]
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical VIVID-1 Phase 3 trial. The study, crucial for those with moderately to severely active Crohn’s disease, has established mirikizumab as a beacon of hope in the treatment landscape. Striking Results […]
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster its immunology pipeline. The California-based Prometheus Biosciences is engaged in the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases by using a […]
In this post let us know about Crohn’s disease diet plan. What foods should be taken and what foods need to be avoided? Crohn’s disease diet plan For patients with Crohn’s disease, a diet plan that is effective for one individual may not be effective for someone else. This is due to the fact that […]
How is Crohn’s disease diagnosed? Crohn’s disease cannot be identified by any single test. The physician will start identifying the condition by eliminating possible causes for the symptoms. Your doctor can use various tests in order to establish an assessment: The results of blood tests can aid your doctor in looking for specific indicators of […]
What is Crohn’s disease? How common is Crohn’s disease? Crohn’s disease is a form of inflammatory bowel disease (IBD). Crohn’s disease typically occurs within the small intestinal tract as well as the colon. This condition can affect any area of your digestive (GI) tract that extends from the mouth to the anus. It may affect […]
AzurRx BioPharma has signed a stock and cash deal worth $229 million to acquire Florida-based clinical-stage biotech company First Wave Bio. The consideration includes payments for certain development, regulatory and sales milestones. First Wave Bio specializes in developing gut-targeted, small molecule therapies for auto-immune inflammatory bowel diseases (IBD) and other serious disorders. The buyer – […]
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & Johnson’s REMICADE (infliximab). This submission marks a significant milestone in Amgen’s efforts to expand its biosimilar portfolio. ABP 710: A Biosimilar to Infliximab ABP 710 is being developed […]
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows the European Commission’s recent approval of Hulio for all indications of the reference product. Hulio will be accessible to patients in Europe as soon as possible, thanks to a partnership between Mylan and Fujifilm Kyowa Kirin Biologics. […]